stock repurchase ProPhase Labs to Repurchase $6M of Common Stock The company plans to repurchase up to $6 million of its common shares over a six-month period, which the company's board will periodically reevaluate. CareDx to Repurchase up to $50M of Common Stock The company plans to purchase common shares through open market, privately negotiated, or other means for up to 24 months. Prenetics Authorizes $20M Share Buyback The Hong Kong-based diagnostics and genetic testing firm will repurchase up to $20 million of its class A ordinary shares during a two-year period. Standard BioTools Authorizes $20M Share Buyback The South San Francisco, California-based life science research tools provider authorized the repurchase of up to $20 million of shares of its common stock through Dec. 31, 2023. QuidelOrtho Board Authorizes $300M Share Repurchase The firm said it will repurchase up to $300 million in shares of common stock while also prioritizing R&D and manufacturing expansion. Jan 22, 2020 4basebio Announces Treasury Share Buyback May 10, 2019 Bruker Authorizes $300M Share Repurchase Program May 6, 2019 Qiagen Q1 Revenues Grow 2 Percent Nov 19, 2018 Myriad Genetics to Repurchase $50M in Shares From Bank of America Sep 7, 2018 Thermo Fisher to Repurchase $2B of its Shares, Acquire BD's Advanced Bioprocessing Business Nov 28, 2017 Bio-Rad Authorizes $250M Share Repurchase Program Jan 18, 2017 Qiagen Details $250M Synthetic Share Repurchase Plan Aug 15, 2016 Qiagen Announces $250M Synthetic Share Repurchase Program Aug 4, 2016 PerkinElmer Q2 Revenues Up 2 Percent; Discloses Bioo Scientific Acquisition Jun 7, 2016 Myriad Genetics Adds $200M to Share Repurchase Program Nov 13, 2015 Thermo Fisher Announces $1B Share Repurchase Plan Nov 13, 2015 Bruker Board OKs $225M Share Repurchase Program Nov 2, 2015 Illumina Launches $250M Share Repurchase Program May 28, 2015 Agilent Board Approves $1.14B Share Buyback Program May 22, 2015 Bruker Authorizes Share Buyback Program May 13, 2015 Qiagen Repurchasing up to $30M of Shares Feb 24, 2015 Myriad Board OKs $200M Share Repurchase Program Aug 6, 2014 Waters Discloses $23M Price Tag for MediMass Technology; New Share Buyback Program Approved Nov 22, 2013 Agilent Board Authorizes Share Repurchase Program, Dividend Sep 12, 2013 Qiagen Initiates Buyback of $10M of Shares Load More Breaking News Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More New Products Posted to GenomeWeb: Qiagen, IDT, Revvity, Mission Bio, NRichDx, More FDA Releases Proposed Rule for Oversight of Laboratory-Developed Tests CStone Pharmaceuticals, Genetron Companion Diagnostic Receives NMPA Approval The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.